SFE-AFCE-SFMN 2022 Consensus on the management of thyroid nodules: Introduction to the consensus - 13/12/22
the group of participants in the SFE-AFCE-SFMN 2022 consensus on the management of thyroid nodules
Abstract |
The SFE-AFCE-SFMN 2022 consensus deals with the management of thyroid nodules, a condition that is a frequent reason for consultation in endocrinology. In more than 90% of cases, patients are euthyroid, with benign non-progressive nodules that do not warrant specific treatment. The clinician's objective is to detect malignant thyroid nodules at risk of recurrence and death, toxic nodules responsible for hyperthyroidism or compressive nodules warranting treatment. The diagnosis and treatment of thyroid nodules requires close collaboration between endocrinologists, nuclear medicine physicians and surgeons, but also involves other specialists. Therefore, this consensus statement was established jointly by 3 societies: the French Society of Endocrinology (SFE), French Association of Endocrine Surgery (AFCE) and French Society of Nuclear Medicine (SFMN); the various working groups included experts from other specialties (pathologists, radiologists, pediatricians, biologists, etc.). This introductory text explains the reasons for this choice and the methodology used, and gives an overview of the current consensus on the management of the thyroid.
Le texte complet de cet article est disponible en PDF.Keywords : Thyroid nodule, Management, Methodology, Consensus overview
Plan
☆ | The list of participants in the SFE-AFCE-SFMN 2022 consensus on the management of thyroid nodules is given at the end of the text. |
Vol 83 - N° 6
P. 375-377 - décembre 2022 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?